FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Although tirzepatide use was associated with elevated amylase and lipase levels, risk for pancreatitis was not elevated among users of tirzepatide vs placebo. Tirzepatide does not yield a significant ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...